The plasma enzyme responsible for primary proteolytic cleavage of growth hormone-releasing hormone (GRH) at the 2-3 amino acid bond was characterized. Native GRHIGRH(144)-NH2 and GRH(140)-OHI, and COOH-terminally shortened fragments [GRH(1-32)-NH2 and GRH(1-29)-NH21 were rapidly cleaved, while GRH(2-32)-NH2 was not degraded at this site. Moreover, degradation to GRH(344)-NH2 was unaffected by an aminopeptidase inhibitor, indicating that this metabolite was generated from a single step cleavage by a dipeptidylpeptidase (DPP) rather than sequential aminopeptidase cleavages. Conversion to GRH(344)-NH2 was blocked by diprotin A, a DPP type IV (DPP IV) competitive inhibitor. D-Amino acid substitution at either position I or 2 also prevented hydrolysis, characteristic of DPP IV. Analysis of endogenous plasma GRH immunoreactivity from a human GRH transgenic pig revealed that the major peak coeluted with GRH(344)-NH2. Native GRH exhibited trypsin-like degradation at the 11-12 position but cleavage at the 12-13 site occurred only with GRH(1-32)-NH2 and GRH(1-29)-NH2. Formation of these metabolites was independent of prior DPP IV hydrolysis but was greatly reduced by trypsin inhibitors. Evaluation of plasma stability of potential GRH super analogues, designed to resist degradation by these enzymes, confirmed that GRH degradation in plasma occurs primarily by DPP IV, and to a lesser extent by trypsin-like enzyme(s). RIA of GRH. GRH was measured by a double antibody RIA as previously described (4, 5). The assay sensitivity was 3 pg/tube and the intraassay coefficient of variation was 3.9%.
Introduction
We have recently reported that human growth hormone-releasing hormone (GRH)', GRH( 1-44)-NH2, is rapidly metabolized by plasma to a biologically inactive fragment lacking the amino-terminal two residues, tyrosine and alanine (GRH(3-44)-NH2) (1) . This metabolite exhibits full crossreactivity in GRH RIA systems and its plasma t/2 is much greater than that of the native hormone both in vivo and in vitro. As a consequence, measurement of plasma immunoreactive GRH levels 1. Abbreviations used in this paper: DPP, dipeptidylpeptidase; GRH, growth hormone-releasing hormone; IR, immunoreactive; TFA, trifluoroacetic acid. results in artifactually elevated levels that include primarily the amino-terminally cleaved metabolite, and possibly other immunoreactive GRH fragments, along with much lower levels of native GRH.
The present study was performed to determine the mechanism(s) responsible and the enzyme(s) involved in this process. We specifically addressed the question of whether the cleavage of the two amino-terminal amino acids occurs by sequential steps involving one or more aminopeptidases or by a single step through the action of a dipeptidylpeptidase (DPP), of which four established classes exist (2) . For this purpose, we tested GRH analogues designed to be resistant to the action of the putative enzyme(s) as well as specific enzyme inhibitors. In addition, we sought evidence for other metabolic fragments derived from native GRH and GRH analogues.
Although our initial study (1) was performed using synthetic GRH(1-44)-NH2, recent characterization of plasma from a patient with ectopic GRH secretion associated with a carcinoid tumor revealed that the majority of GRH immunoreactivity was in the form of GRH(3-40)-OH (3) . In the present report we also provide evidence for similar metabolism in another model of GRH hypersecretion, the transgenic hGRH pig.
Methods
Incubation, extraction, and HPLC ofpeptides incubated with plasma. Synthetic human GRH(1-44)-NH2, GRH(l-40)-OH, GRH(1-32)-NH2, GRH(l-29)-NH2 or various analogues were dissolved in 5 mM acetic acid (10 mg/ml) and added to human plasma in a ratio of 100 g peptide to I ml plasma as previously described (1) . A 0.25-1.0-ml aliquot was immediately withdrawn, mixed with 0.25 ml 1 M trifluoroacetic acid (TFA)/ml plasma, and applied to a C18 reverse phase Sep-Pak cartridge (Waters Associates, Milford, MA) that had been previously activated with 5 ml each 0.01 M TFA, 80% acetonitrile in 0.01 M TFA, and 0.01 M TFA. After washing with 5 ml 0.01 TFA, GRH and its fragments were eluted from the cartridge with 2 ml 80% acetonitrile in 0.01 M TFA and lyophilized. The remaining plasma containing GRH was incubated at 37°C for 60 min in a shaking water bath at 60 rpm, then extracted in the same manner. HPLC was performed on a 250 X 4.6-mm Vydac 201 TP or 218 TP reverse phase C18 column using a Varian System instrument (model 5020; Varian Associates Inc., Palo Alto, CA). Samples were resuspended in 0.2 ml 0.01 M TFA, applied to the column that had been previously equilibrated with 0.01 M TFA-29% acetonitrile, and eluted isocratically for 10 min, followed by a shallow acetonitrile gradient (1%/l 5 min) at a flow rate of I ml/min. The elution position for each of the analogues was determined in a preliminary experiment before performing the incubation with plasma. Peptide peaks were detected by absorption at 210 nm and their areas determined by triangulation. Fractions were collected at 1-min intervals and Iyophilized for GRH RIA or amino acid sequence analysis.
Peptides, enzyme inhibitors, and other materials. GRH( -44)NH2, GRH(l-29)NH2, and their analogues were synthesized by the Merrifield solid-phase procedure (6, 7) and purified as previously described (1) . GRH( -32)NH2 and GRH(2-32)NH2 were generously provided by Dr. J. Rivier Amino acid analysis and sequencing. Amino acid analysis of peptide peaks generated from the incubation of GRH with plasma were performed on an instrument using a postcolumn reaction method with fluorescamine (8) . Microsequence analysis was carried out on a sequencer (model 470A; Applied Biosystems, Inc. Foster City, CA) (9). PTH-amino acids at each cycle were identified by HPLC (10) .
Results
Incubation of GRH(1-44)-NH2 and carboxy-terminal shortened forms of GRH with human plasma in vitro. As seen in Table I , GRH( 1-44)-NH2, GRH( 1-40)-OH, GRH( 1-32)-NH2, and GRH( 1-29)-NH2 were all rapidly cleaved during incubation with plasma at the 2-3 position, as confirmed by sequence analysis of the major metabolite peak. The percent degradation of GRH(l-44)-NH2, GRH(l-32)-NH2, and GRH(l-29)-NH2, as determined by the area under the curve, was similar, while GRH( 1-40)-OH was slightly more stable, confirming our previous observations (1) . However, the percentage ofthe original peptide present as GRH(3-44)-NH2, GRH(3-40)-OH, GRH(3-32)-NH2, and GRH(3-29)-NH2 after the 60-min incubation period was virtually identical. The separation time between the native peptides and the des(Tyr' Ala2) metabolites also remained relatively constant (10-12 min) on our HPLC system irrespective of the length of the parent compound.
Diferentiation between aminopeptidase and DPP degradation of GRH. The HPLC absorbance profile from one of the previously discussed peptides, GRH(1-32)-NH2, is shown in Fig. 1 . The top panel shows the ultraviolet (UV) absorbance profile at 210 nm of GRH(1-32)-NH2 added to plasma, but without incubation (time 0). Incubation of GRH(1-32)-NH2 with plasma resulted in the formation of a new peak (peak C, Fig. 1 , middle) with a HPLC retention time of 47 min as compared with 58 min for GRH(1-32)-NH2. This peak was identified as GRH(3-32)-NH2 by amino acid sequence analysis. Cochromatography of GRH(3-32)-NH2 together with 10 gg each of synthetic GRH(2-32)-NH2 and GRH(1-32)-NH2 using the same HPLC elution conditions revealed clear resolu-tion of the three peptides (Fig. 1 , bottom). However, no peak corresponding to GRH(2-32)-NH2 could be identified on the HPLC elution profile of GRH(1-32)-NH2 after incubation with plasma ( Fig. 1, middle) . Other newly generated peaks, designated A at 14 min and B at 22 min, are discussed later.
The elution profile of GRH(2-32)-NH2 before (top) and after (bottom) incubation with plasma is shown in Fig. 2 . No evidence of a peak corresponding to GRH(3-32)-NH2 (Fig. 2 , bottom) was seen, and only 56% of the GRH(2-32)-NH2 was degraded during the 60-min incubation as compared with 89% degradation for GRH(1-32)-NH2 (Table I) under the same conditions. However, the formation of other metabolites with shorter retention times (14 and 22 min), which were identical to peaks A and B from the degradation of GRH(1-32)-NH2 ( Fig. 1, middle) , was unaffected. during incubation with plasma (not shown). Only 54% of the peptide was degraded, but two earlier peaks, identical to peaks D and E in Fig. 3 , were observed.
The effect of several enzyme inhibitors on the degradation of GRH(l-44)-NH2 in plasma were examined next. The metabolism of GRH(1-44)-NH2 in the absence of any enzyme inhibitors is shown in Fig. 4 a as reference. After 60 min of incubation in plasma, 95% of the GRH(l-44)-NH2 was degraded ( Fig. 4 b) and two additional peaks, designated F (8 min) and G (GRH(3-44)-NH2, 38 min), were apparent. Incubation of GRH(1-44)-NH2 with plasma in the presence of 1 mM 1,10-phenanthroline, a chelating agent that inhibits aminopeptidase activity (2, 1 1), is shown in Fig. 4 c. Conversion of GRH(1-44)NH2 to GRH(3-44)-NH2 (peak G at 38 min) was not prevented by 1,10-phenanthroline and the overall degradation of GRH(l-44)-NH2 (9 1%) was also unaffected.
Peak F (8 min) was also observed in the presence of the aminopeptidase inhibitor. The effect of diprotin A, a bacterial tripeptide (Ile-Pro-Ile) that competitively inhibits DPP IV (12) , is shown in Fig. 4 d. The presence of 1 mM diprotin A during the plasma incubation greatly reduced the conversion of GRH(1-44)-NH2 to GRH(3-44)-NH2. Peak F (8 min) was GRH(3-44)-NH2 38 28 GRH ( again observed and the overall degradation of GRH(1-44)-NH2 was reduced to 82%.
Characterization ofother degradative products ofGRH and analogues. Several of the earlier eluting HPLC peaks that were observed after plasma degradation of the previously discussed GRH peptides and analogues (Figs. 1-4) were also subjected to amino acid composition and NH2-terminal sequence analysis. They were identified as COOH-terminal fragments resulting from cleavage at one or both of the basic residues, Arg and Lys, at positions 11 Incubation of GRH(1-44)-NH2 with plasma in the presence of the trypsin inhibitor, Trasylol (500 KIU/ml plasma), resulted in much less generation of GRH( 12-44)-NH2 (peak F, Fig. 4 e) . However, the overall degradation ofGRH( 1-44)-NH2 was still 82% and the GRH(3-44)-NH2 peak was 3.3-fold greater than in the absence of the inhibitor. Virtually identical results were observed with another trypsin inhibitor, Foy 007 (1 mM, not shown). The combination of 1 mM diprotin A and 500 KIU/ml Trasylol greatly decreased the generation of both GRH(3-44)-NH2 and GRH(12-44)-NH2 and reduced the overall degradation of GRH(1-44)-NH2 to 18% (Fig. 4f ). Effects ofother modifications and substitutions on the degradation ofGRH by plasma. Several other modifications ofthe NH2-terminal tyrosine residue, including deamination or acet-ylation, completely inhibited cleavage at the 2-3 position (DPP) but did not prevent trypsin-like cleavage at the 11-12 (TL-1) and/or [12] [13] (TL-2) positions (Table II) . Substitution of Tyr' with Phe' or 3-MeHis' did not inhibit generation of any of the metabolites. The replacement of Gly'5 with Ala'5, resulting in increased a-helicial conformation and amphiphilic structure (13) , did not reduce DPP hydrolysis, but decreased cleavage by the trypsin-like enzyme(s), resulting in an overall metabolism of only 65%. Concurrent substitution with Leu27, Asn28, designed to reduce loss of biological activity due to oxidation of the native Met27 residue, resulted in slightly more stable forms using 32 or between the f3-carboxyl and e-amino groups (14) , in combination with Ala'5 substitution, completely inhibited the trypsinlike cleavages and resulted in only very limited degradation by DPP (Table II) . Substitution ofAsn8 with Asp8 and subsequent side-chain to side-chain cyclization with Lys'2 also completely blocked trypsin-like metabolism and reduced DPP cleavage. The further inclusion of D-Ala2 in this analogue reduced overall degradation to 7% and no metabolites were seen. Characterization of GRH immunoreactivitj in plasma from a transgenic pig. The HPLC elution profile of plasma from a hGRH transgenic pig is shown in Fig. 6 . The total plasma concentration of immunoreactive (IR) GRH was 5.5 ng/ml. The largest peak of plasma IR-GRH coeluted with GRH(3-44)-NH2, while only a small quantity (-5%) of the total immunoreactivity eluted in the location of GRH(1-44)-NH2. Other small identifiable immunoreactive peaks were observed at 41 (GRH(3-40)-OH), 53 (GRH(l -40)-OH), and 80 min (a possible GRH prohormone, as based on preliminary data [not shown]).
Discussion
The isolation and sequencing of human GRH has indicated that two forms of the hormone exist in the hypothalamus, GRH(1-44)-NH2 and GRH(1-40)-OH (15) . Several studies have demonstrated the potential efficacy of GRH for treatment of certain types of growth deficiency in children (16) as well as accelerated growth and milk production in livestock (17, 18) . However, the short t,12 (6-10 min) (1) of the native peptides limit their therapeutic usefulness. Since full biological activity of GRH resides within the first 29 amino acids (19, 20) , development of GRH analogues with enhanced and/or prolonged activity has focused on this COOH-terminally shortened form.
The results of our previous study (1) showed that the primary metabolites of the native GRH peptides in plasma, in vivo and in vitro, were GRH(3-44)-NH2 and GRH(3-40)-OH. These metabolites were more stable than native GRH in plasma, but were virtually completely biologically inactive. The present data demonstrate that COOH-terminally abbreviated fragments of GRH of at least 29 residues were similarly degraded. Moreover, the metabolism of several forms of GRH clearly indicated that this cleavage was due to the action of a DPP rather than the sequential cleavage of the tyrosine and alanine residues by one or more aminopeptidase(s). The degradation of GRH(1-44)-NH2 to GRH(3-44)-NH2 was not pre- DPP subgroup of exopeptide hydrolases (2, 21), of which only DPP IV [EC 3.4.14.5] has the necessary substrate specificity and pH activity optimum (7.8) to hydrolyze GRH in plasma. DPP IV is found in the highest levels as a microvillus membrane-bound enzyme in the kidney, but also as a microsomal membrane-associated and soluble protein in numerous tissues including liver, spleen, skin, jejunum, lung, submaxillary gland, and brain (1 1, 22-25) . In addition, DPP IV is present in high concentrations as a soluble enzyme in serum, saliva, and cerebrospinal fluid (1 1, 22, 25, 26) . DPP IV has been classified as a serine protease and exists in a dimeric structure consisting of two identical subunits, each with one active site and a molecular mass of -130,000 D (23). DPP IV hydrolysis occurs on the COOH-terminal side of the second amino acid in peptides only if the second residue is proline or alanine (2, 27) . Its action results in the release ofthe intact NH2-terminal dipeptide. Though proline is the preferred second residue, peptides with alanine in the penultimate position, especially in conjunction with a bulky, hydrophobic NH2-terminal residue (such as tyrosine), are readily cleaved by DPP IV (2, 27) . A free amino group on the NH2-terminal residue is also required, demonstrating the exopeptidase property ofthe enzyme. In addition, DPP IV cleavage is blocked by the substitution of D-amino acid stereoisomers of either the NH2-terminal or penultimate residue. This characteristic is unique among the known DPPs to DPP IV, since DPPs I-III require L-amino acids only in the second position (2) . All (25) , it is possible that the conformation of the primary GRH metabolite could deny DPP IV access to these residues (Asp3-Ala4-Ile5). Initial screening of several of the above DPP IV-protected GRH analogues and GRH(3-44)-NH2 showed that these peptides were still metabolized to the extent of40-50% during our standard in vitro plasma incubation. Since our original study revealed small amounts ofGRH immunoreactivity that eluted near the void volume of our HPLC system, we modified the HPLC conditions to attempt to identify this metabolite(s). A 9-min peak with limited crossreactivity in our GRH RIA, based on the size of its UV absorbance peak, was initially detected after plasma incubation with GRH( 1-44)-NH2. The metabolite was identified as GRH(12-44)-NH2 and appeared to be the product of a trypsin-like enzymatic hydrolysis at the Arg' -Lys'2 bond. This metabolite was also observed using DPP IV-protected analogues and GRH(3-44)-NH2 (not shown), suggesting that the trypsin-like cleavage occurs independently of DPP IV degradation. Two different trypsin inhibitors, Trasylol and Foy 007, greatly reduced the formation of the GRH( 12-44)-NH2 metabolite.
A third GRH metabolite, detected by UV absorbance only with the GRH(1-32)-NH2 and GRH(1-29)-NH2 forms and certain of their analogues, was identified as another trypsinlike cleavage product, GRH(13-32)-NH2 and GRH(13-29)-NH2. Inability to detect this form with native GRH peptides cannot be presently explained. However, the amount of GRH(13-32)-NH2 detected was quite small relative to GRH(12-32)-NH2, and only when GRH(l-29)-NH2 and its analogues were used as substrates did the amount ofGRH(13-29)-NH2 exceed that of GRH( 12-29)-NH2. Both of these metabolites appear to result from trypsin-like hydrolysis, however, since incubation of GRH(1-29)-NH2 in the presence of Trasylol prevented the formation of GRH(12-29)-NH2 and GRH(13-29)-NH2, while 1, 10-phenanthroline did not stop degradation to GRH(1 3-29)-NH2 (not shown). Whether these metabolites are formed by successive or independent 11-12 and 12-13 cleavages as well as the number of trypsin-like enzymes involved is unknown. Other GRH analogues were designed in an attempt to increase biological activity by maximizing amphiphilic structure and extending the a-helical region of GRH(1-29)-NH2. Substitution of Ala'5 for Gly"5 created a nearly ideal a-helical structure between residues 3-29 and enhanced intrinsic biological activity (28) . Degradation of this analogue by both trypsin-like enzymes was greatly diminished. The increased plasma stability observed with additional substitution of Leu27, Asn28 may be attributed to the use of forms of GRH with a free carboxy terminus, as shown for GRH(1-40)-OH. The trisubstituted, DPP IV-protected compound, [desNH2Tyrl, D-Ala2, Ala`5]-GRH(1-29)-NH2, displayed greater stability than the DPP IV-protected analogues alone due to its resistance to trypsin-like hydrolysis. Cyclization of the f3-carboxyl group of the native Asp3 residue to the e-amino group of the Lys'2 residue (and Ala'5 substitution), produced an analogue that was resistant to both DPP IV and trypsin-like degradation due to the side-chain modifications of residues 3 and 12 that are required for enzyme recognition. Furthermore, side-chain to side-chain cyclization of substituted Asp8 with Lys'2 (and Ala'5 substitution), with or without DPP IV protection (D-Ala2), resulted in analogues that displayed nearly complete resistance to both DPP IV and trypsin-like degradation. These observations are explained on the basis of enhancement of a-helical structure (28) and side-chain modification of residue 12.
DPP IV hydrolysis of several other bioactive peptides by plasma or partially purified preparations of DPP IV has been previously reported. The opioid peptide, fl-casomorphine (NH2-Tyr'-Pro-Phe-Pro-Gly-Pro-Ile7-OH) is rapidly degraded by three successive DPP IV cleavages and D-amino acid substitutions (Ala or Pro) in position 2 has resulted in analogues with greatly increased stability (29, 30) . Substance P (NH2-Arg'-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met' '-NH2) is also sequentially cleaved by DPP IV at the 2-3 and 4-5 sites (31, 32) . In contrast to GRH metabolites, substance P (3-1 1)-NH2 and (5-1 )-NH2 metabolites exhibit intact or increased potency (33) and possibly even different functions, as compared with the parent compound, in several regions of rat brain (34) . Many other human brain and gut peptides also contain NH2-terminal sequences that predict susceptibility to DPP IV hydrolysis (though none have yet been reported), including corticotropin-like intermediate lobe protein (ACTH(18-39)), gastic inhibitory polypeptide, gastrin-releasing peptide, neuropeptide Y, pancreatic polypeptide, peptidehistidine-methionine, peptide YY, somatomedin C (IGF-I), and somatostatin 28.
The critical importance ofthe NH2 terminus for the biological activity of GRH has been documented by several groups (35, 36) . NH2-terminal deletions through only the first three residues reduced bioactivity to < 0.02% of GRH( 1-44)-NH2 (35). Substitution of Tyr' with residues other than His produced a similar effect (36) . Thus, the first superactive GRH analogues were designed by stabilizing the NH2-terminal residues, primarily with D-amino acid substitutions (36) (37) (38) . The reported increase in the intrinsic activity of some of these analogues in vitro by some investigators (37, 38) remains controversial (36) . However, the in vivo potency of these peptides was undoubtedly enhanced (37), due in large part to their resistance to DPP IV degradation as we have now shown. More recently, it has been shown by us (39) and others (40) that active GRH analogues that are resistant to both DPP IV and trypsin-like enzymatic degradation exhibit even greater biological potency in vivo than DPP IV-protected analogues alone.
The physiological importance of the rapid degradation of GRH by DPP IV and other enzymes in the regulation of GH secretion is presently unknown. It is conceivable that these enzymes in serum and tissues exert a regulatory role to ensure rapid inactivation of GRH and other bioactive peptides so as to limit their biologic effects to nearby target tissues by a single pass effect, as has been proposed by others (41) . The action of these enzymes, however, emphasizes the importance of the development of resistant analogues for potential therapeutic and animal science use. Indeed, we have recently characterized the plasma GRH immunoreactivity in a patient with acromegaly due to an ectopic GRH-producing tumor (3) . Plasma IR-GRH levels before treatment were nearly 10 ng/ml, but after HPLC separation, intact, native GRH forms were shown to make up only 5-10% of the total circulating GRH immunoreactivity. In this study, similar results have been shown for the plasma IR-GRH from the human GRH transgenic pig and we have also observed the same pattern in hGRH transgenic mice (42). Thus, continuous circulating levels of intact GRH (as opposed to total IR-GRH) as low as 100-200 pg/ml may be sufficient to produce persistent GH hypersecretion. A recent report by Sawano and co-workers has confirmed our results by showing that the major metabolite of GRH(1-29)-NH2 in plasma is GRH(3-29)-NH2 (43). While we have not observed the secondary Thr7-Asn8 cleavage that they reported only with the [D-Ala2]-GRH( 1-29)-NH2 analogue, our results do not rule out the possibility of the formation of other minor GRH metabolites.
In conclusion, GRH is rapidly degraded in plasma by DPP IV and trypsin-like enzyme(s) to peptides with virtually no GH-releasing activity. Based on the sites of hydrolysis of GRH by these enzymes, and the structural and conformational requirements for substrate activity, a series of degradation-resistant GRH (super) analogues have been developed for potential clinical and animal science use.
